USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Companion Diagnostics Market – Growth Opportunities, Analysis, Forecast, Global, 2022
The Transition To Precision Medicine Is Propelling The Adoption Of Cdx Platforms.,Cdx Companion Diagnostics,Companion Diagnostics Market,Companion Diagnostics Oncology
13-Dec-2022
Global
Technology Research
DA87-01-00-00-00
HC03611-GL-TR_27252
$4,950.00
Special Price $3,712.50 save 25 %
The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiological effects. CDx help medical professionals make better drug therapy choices for patients.
A CDx assay is an IVD device that provides information regarding the safety, efficacy, and monitoring of a particular therapeutic product for a patient.
A CDx assay combines with a drug to form a drug-diagnostic co-development model. A strong biomarker correlation is responsible for this model's success that preclinical research deduces. A CDx assay undergoes analytical and clinical validation and is useful only if it successfully discriminates between a responder and a non-responder.
This Frost & Sullivan study discusses recent trends in CDx developments and their impact on bolstering precision medicine. The study also analyzes upcoming innovation across nucleic acid-based tests, immunoassays, molecular imaging techniques, and multimodal diagnostics. Furthermore, it explores developments in liquid biopsies, next-generation sequencing (NGS) platforms, fluorescence in-situ hybridization (FISH) techniques, and other genetic analysis tools that aid the discovery and development of novel biomarkers for new CDx products and services. The study also discusses global regulatory aspects and the need to streamline policies for accelerated government approvals.
Key Questions the Study Answers:
How are CDx and therapies co-developed?
What are the regulatory requirements for CDx development?
What are the key partnership and funding trends for CDx technologies?
What are the emerging innovations in CDx technologies?
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Companion Diagnostics (CDx) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Introduction to CDx
Role of CDx in Precision Medicine
Scope
Segmentation
Growth Drivers
Growth Restraints
CDx and Therapeutics Co-development
CDx and Therapeutics Co-development (continued)
Regulatory Requirements for CDx
Regulatory Requirements for CDx (continued)
Summary of Strategic Pharma and Diagnostic Collaborations
Summary of Strategic Pharma and Diagnostic Collaborations (continued)
Overview of Funding Trends
Overview of Tissue CDx Technologies
Workflow Summary for Using AI in Digital Pathology
US FDA-approved Tissue CDx Applications in Oncology
Emerging CDx Applications in Oncology
CDx Application Landscape for Non-cancer Indications
Emerging Trends for Tissue CDx Use in Non-cancer Indications
Outlook for Tissue CDx Platforms
Overview of Liquid Biopsy Platforms
Overview of Liquid Biopsy Analytes and Isolation Technologies
Comparative Analysis of Tissue and Liquid Biopsies
Snapshot of Liquid Biopsy Applications in Cancer Treatment
Key Biomarkers for Top 3 US FDA-approved Liquid Biopsy Indications
Emerging Clinical Trial Landscape for Liquid Biopsy Platforms
Snapshot of Liquid Biopsy Clinical Trials
Outlook for Liquid Biopsy Platforms
Components of Imaging-based CDx
Advantages of Using Imaging-based CDx
Summary of Trends Driving the Growth of Imaging-based CDx
Small Molecules used for Molecular Imaging-based CDx
Peptides Used for Molecular Imaging-based CDx
Antibodies for Molecular Imaging-based CDx
Emerging Clinical Trial Landscape for Imaging-based CDx
Overview of Imaging-based CDx for Non-oncological Indications
Outlook for Imaging-based CDx Platforms
Analyst Perspectives
Growth Opportunity 1: Tissue Multiplexing and Digital Pathology
Growth Opportunity 1: Tissue Multiplexing and Digital Pathology (continued)
Growth Opportunity 2: NGS-based Liquid Biopsy
Growth Opportunity 2: NGS-based Liquid Biopsy (continued)
Growth Opportunity 3: Hybrid Imaging-based CDx
Growth Opportunity 3: Hybrid Imaging-based CDx (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
26 Aug 2026 | Global | Technology Research
Growth Opportunities and Advancements in Acute and Chronic Wound Care
A wound is any disruption in the normal structure and function of the skin or underlying tissues. It can result from physical injury, surgery, or underlying medical conditions. Wounds are broadly classified into two categories: acute wounds and chronic wounds. Acute wounds typically heal through the...
26 Aug 2026 | Global | Frost Radar
Frost Radar™: Healthcare Infrastructure Cybersecurity in the United States, 2026
Healthcare organizations are expanding their digital environments across cloud infrastructure, connected medical devices, applications, identities, operational technology, and distributed care settings, creating a broader and increasingly interconnected attack surface. Cybersecurity is, therefore, e...
25 Aug 2026 | Global | Technology Research
Breakthrough Innovations in Point-of-Care Diagnostics
This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.
The study assesses key technology shifts, including rapid molecular t...
25 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Digital Biomarkers
A digital biomarker refers to measurable data about physiological functions or behaviors collected through digital devices and technologies, such as wearables, implants, ingestible sensors, smartphones, and mobile applications.
These biomarkers provide continuous, real-time insights into an ...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| New Title | Companion Diagnostics Market – Growth Opportunities, Analysis, Forecast, Global, 2022 |
|---|---|
| New Subtitle | The Transition To Precision Medicine Is Propelling The Adoption Of Cdx Platforms.,Cdx Companion Diagnostics,Companion Diagnostics Market,Companion Diagnostics Oncology |
| Deliverable Type | Technology Research |
| Author | Swati Mishra |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | CDX Companion Diagnostics |
| Keyword 2 | Companion Diagnostics Market |
| Keyword 3 | Companion Diagnostics Oncology |
| Podcast | No |
| WIP Number | DA87-01-00-00-00 |